Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ayman Samkari

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
JAMA Oncology|June 4, 2021
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized TrialSalma K Jabbour, Ki Hyeong Lee, Nikolaj Frost, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 30, 2023
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 TrialJames Chih-Hsin Yang, Baohui Han, Emmanuel De La Mora Jiménez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2021
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLCRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 StudyMichael Boyer, Mehmet A N Şendur, Delvys Rodríguez-Abreu, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 24, 2026
A subgroup analysis of perioperative pembrolizumab in clinical stage II non-small-cell lung cancer from the randomized keynote-671 studyMasahiro Tsuboi, Heather Wakelee, Marina C Garassino, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinomaJason J Luke, Georgina V Long, Caroline Robert, et al.
Lancet (London, England)|September 17, 2024
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialJonathan D Spicer, Marina C Garassino, Heather Wakelee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2020
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 StudyRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
JAMA Oncology|June 4, 2021
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized TrialSalma K Jabbour, Ki Hyeong Lee, Nikolaj Frost, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 30, 2023
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 TrialJames Chih-Hsin Yang, Baohui Han, Emmanuel De La Mora Jiménez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2021
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLCRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 StudyMichael Boyer, Mehmet A N Şendur, Delvys Rodríguez-Abreu, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 24, 2026
A subgroup analysis of perioperative pembrolizumab in clinical stage II non-small-cell lung cancer from the randomized keynote-671 studyMasahiro Tsuboi, Heather Wakelee, Marina C Garassino, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinomaJason J Luke, Georgina V Long, Caroline Robert, et al.
Lancet (London, England)|September 17, 2024
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialJonathan D Spicer, Marina C Garassino, Heather Wakelee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2020
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 StudyRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.
Pageof 4